Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - MADRIGAL PHARMACEUTICALS, INC. | a2197161z10-k.htm |
| EX-23.2 - EXHIBIT 23.2 - MADRIGAL PHARMACEUTICALS, INC. | a2197161zex-23_2.htm |
| EX-32.1 - EXHIBIT 32.1 - MADRIGAL PHARMACEUTICALS, INC. | a2197161zex-32_1.htm |
| EX-31.2 - EXHIBIT 31.2 - MADRIGAL PHARMACEUTICALS, INC. | a2197161zex-31_2.htm |
| EX-31.1 - EXHIBIT 31.1 - MADRIGAL PHARMACEUTICALS, INC. | a2197161zex-31_1.htm |
| EX-10.30 - EXHIBIT 10.30 - MADRIGAL PHARMACEUTICALS, INC. | a2197161zex-10_30.htm |
| EX-10.31 - EXHIBIT 10.31 - MADRIGAL PHARMACEUTICALS, INC. | a2197161zex-10_31.htm |
| EX-10.29 - EXHIBIT 10.29 - MADRIGAL PHARMACEUTICALS, INC. | a2197161zex-10_29.htm |
QuickLinks -- Click here to rapidly navigate through this document
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement (Form S-3 No. 333-152833) of Synta Pharmaceuticals Corp. and in the related Prospectus, Registration Statement (Form S-8 No. 333-141903) pertaining to the 2001 Stock Plan, the 2006 Stock Plan and the Non-qualified Stock Option Agreement dated May 27, 2004, and Registration Statement (Form S-8 No. 333-152824) pertaining to the Amended and Restated 2006 Stock Plan of Synta Pharmaceuticals Corp., of our reports dated March 11, 2010, with respect to the consolidated financial statements of Synta Pharmaceuticals Corp. and the effectiveness of internal control over financial reporting of Synta Pharmaceuticals Corp. included in this Annual Report (Form 10-K) for the year ended December 31, 2009.
|
/s/ Ernst & Young LLP |
Boston,
Massachusetts
March 11, 2010
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM